What is HC Wainwright’s Forecast for MediWound Q2 Earnings?

MediWound Ltd. (NASDAQ:MDWD) – Stock analysts at HC Wainwright upped their Q2 2025 earnings per share estimates for MediWound in a research note issued on Thursday, May 22nd. HC Wainwright analyst S. Ramakanth now expects that the biopharmaceutical company will post earnings of ($0.55) per share for the quarter, up from their prior estimate of ($0.66). HC Wainwright currently has a “Buy” rating and a $31.00 target price on the stock. The consensus estimate for MediWound’s current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for MediWound’s Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.63) EPS, Q1 2026 earnings at ($0.55) EPS, Q2 2026 earnings at ($0.41) EPS, Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.60) EPS, FY2027 earnings at ($1.34) EPS, FY2028 earnings at ($0.82) EPS and FY2029 earnings at $1.13 EPS.

A number of other brokerages have also issued reports on MDWD. Wall Street Zen raised MediWound to a “sell” rating in a research report on Friday, March 21st. Alliance Global Partners started coverage on MediWound in a research note on Friday, May 2nd. They issued a “buy” rating and a $25.00 price target for the company. Finally, Craig Hallum started coverage on MediWound in a research note on Friday, February 28th. They issued a “buy” rating and a $39.00 price target for the company. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.25.

MediWound Stock Performance

Shares of NASDAQ MDWD opened at $20.37 on Monday. MediWound has a 1 year low of $12.78 and a 1 year high of $24.00. The firm has a market cap of $220.16 million, a price-to-earnings ratio of -7.02 and a beta of 0.30. The stock’s 50-day simple moving average is $17.46 and its 200-day simple moving average is $17.63.

MediWound (NASDAQ:MDWD) last announced its earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.58. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. The business had revenue of $3.96 million for the quarter, compared to analyst estimates of $5.20 million. During the same period in the previous year, the company earned ($1.05) earnings per share.

Hedge Funds Weigh In On MediWound

Hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC grew its stake in MediWound by 1,507.1% in the first quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 1,703 shares in the last quarter. R Squared Ltd bought a new position in MediWound in the fourth quarter worth about $32,000. Russell Investments Group Ltd. lifted its holdings in MediWound by 154.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 1,162 shares during the last quarter. Corebridge Financial Inc. lifted its holdings in MediWound by 17.1% in the first quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 665 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in MediWound by 22.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after acquiring an additional 999 shares during the last quarter. 46.83% of the stock is currently owned by institutional investors and hedge funds.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.